Elite Pharmaceuticals has signed a license, manufacturing, and supply agreement with Glenmark Pharmaceuticals, Inc., USA to market two Elite generic products in the U.S. with the option to add products in the future. 

Glenmark will sell and distribute the products and Elite will receive manufacturing and license fees. Glenmark will have semi-exclusive marketing rights to the ANDA approved product, phendimetrazine 35 mg tablets and exclusive marketing rights to an undisclosed pain product, currently under review by the FDA. Collectively, the brand products and their generic equivalents had total annual sales of approximately $33.6 million in 2017 according to QuintilesIMS Health data.

“The alliance with Glenmark will broaden market access for Elite’s generic products,” said Nasrat Hakim, president and chief executive officer of Elite. “We are excited about the opportunity and look forward to adding more products to the alliance and continued growth for both companies. In addition to our SequestOx NDA filing, Elite currently has five ANDAs under review at the FDA, including two with our partner SunGen Pharma, and eight commercial products.”